{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 13,
  "pageCount": 40,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses Kaplan-Meier survival curves to demonstrate clinical efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/13",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.09,
        "y": 0.36
      },
      "kind": "chart",
      "text": "PACIFIC updated OS (ITT)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cb7c176-f016-48d1-b374-7c83dcce1838",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.68,
        "y": 0.36
      },
      "kind": "chart",
      "text": "HUDSON Phase II + ceralasertib",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75f58139-2677-4739-8d45-0709011c23b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.38,
        "y": 0.36
      },
      "kind": "chart",
      "text": "CASPIAN",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a176b504-839c-4595-93ab-dc2eff3e5386",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.28,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "43% of patients alive at five years; 33% progression free at five years",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1115e819-8844-4c78-a3e1-ee7957520ad9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.28,
        "x": 0.36,
        "y": 0.62
      },
      "kind": "list",
      "text": "Only IO medicine with two-year OS published data; 3-year exploratory data anticipated in H2 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3aff1a46-15e1-41f5-ae97-1f98ee9bb4f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.28,
        "x": 0.67,
        "y": 0.62
      },
      "kind": "list",
      "text": "Post-checkpoint inhibitor use - overcome immune checkpoint resistance through ceralasertib + Imfinzi combination",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "841b9ff5-8f2a-4ae1-b0e0-cdd1223187c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Ongoing Phase III trials: Unresectable: PACIFIC-2, PACIFIC-4, PACIFIC-5, PACIFIC-8; Resectable: AEGEAN, BR.31, MeRmaiD 1/2",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abc3b599-352b-443e-a013-b45fc243c1b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.36,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Ongoing Phase III trials: Limited stage: ADRIATIC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc3480f1-abe1-4307-b13e-0bb067a76b0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.67,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Ongoing Phase II trials: HUDSON (advanced NSCLC post CPI), MAGELLAN (1L NSCLC), NeoCOAST (resectable NSCLC, neoadjuvant), COAST (Imfinzi + novel MoAs)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fca7a033-a3ba-4bfd-a2d0-499454ecdd98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "1.Intention to treat. 2.Extensive-stage small cell lung cancer. 3.Checkpoint inhibitors 4. Mode of action. Source: abstract 8511, ASCO 2021. Source: Journal of Clinical Oncology 38, no. 15_suppl (20 May 2020) 9002-9002. Source: abstract OA07.08, WCLC 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65971b8e-974c-4acf-968b-6b9d1df56884",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "title",
      "text": "Imfinzi: immuno-oncology Unique position in lung cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5caf2823-2930-40f6-bcb1-a6591b2c86d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "c80a7fa5-a0e9-4ce8-8f7c-8e846d17fef5",
      "evidence": "TROPION-PanTumor01 waterfall plot",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "6407b6da-054c-43a3-924f-c8af0ea8759b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document showcases AstraZeneca's pipeline and progress in various areas of oncology, providing satisfaction to investors.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}